Thus, the CD8/CD163 ratio can potentially impact the decision-making process regarding mTNBC therapies, specifically harnessing the full capability of the immune system in combating cancer (Table 2, Fig. 1E) [23, 26]. The gene discussed is CD163; the disease is cancer.